Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Director · President and CEO; Director | July 27, 2019 | July 30, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date July 27, 2019 · Filed July 30, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,289 |
Reported balance
After 2019-07-27 transaction · row 1
1 source rowRow 1 · 2019-07-27 · Tax withholding · Disposed 2,147 · Balance 20,289 F1: Reflects an aggregate of 2,147 shares of common stock retained by the Issuer to satisfy tax withholding obligations. F2: Reflects the closing price of the ANIK common stock on July 26, 2019, the last trading day prior to the vesting of restricted shares giving rise to tax withholding obligations. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an aggregate of 2,147 shares of common stock retained by the Issuer to satisfy tax withholding obligations.
F2: Reflects the closing price of the ANIK common stock on July 26, 2019, the last trading day prior to the vesting of restricted shares giving rise to tax withholding obligations.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2019 Filed Jul 30, 2019 20:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 2,147 | $55.85 | $119,909.95 |
DisclosureSEC source: 0001171843-19-004978 · ownership.xml · nonDerivative · entry 1 Darling Joseph G · CIK 0001433556 · Director · President and CEO; Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,289 F1 · shares: Reflects an aggregate of 2,147 shares of common stock retained by the Issuer to satisfy tax withholding obligations. F2 · price: Reflects the closing price of the ANIK common stock on July 26, 2019, the last trading day prior to the vesting of restricted shares giving rise to tax withholding obligations. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 13:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | PurchaseCommon Stock | 1,000 | $33.20 | $33,200.00 |
DisclosureSEC source: 0001171843-19-001414 · ownership.xml · nonDerivative · entry 1 Darling Joseph G · CIK 0001433556 · Director · President and CEO; Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,436 Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 21:32 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 7,609 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-19-001386 · ownership.xml · derivative · entry 2 Darling Joseph G · CIK 0001433556 · Director · President and CEO; Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,609 Underlying: Common Stock · 7,609 shares Expires 2028-01-24 F2 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 24, 2018, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 3 and 4. F3 · date: On February 27, 2019, the Compensation Committee determined and certified that 53.2% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 2 and 4. F4 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 27, 2019, January 1, 2020, January 1, 2021, and January 1, 2022. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:32 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 63,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001386 · ownership.xml · derivative · entry 1 Darling Joseph G · CIK 0001433556 · Director · President and CEO; Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020, provided that the first installment of shares hereunder shall be delivered upon the first to occur of Mr. Darling's (a) death, (b) disability, (c) separation from service (as defined by the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the "Plan")), or (d) a Change in Control (as defined by the Plan). F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020, provided that the first installment of shares hereunder shall be delivered upon the first to occur of Mr. Darling's (a) death, (b) disability, (c) separation from service (as defined by the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the "Plan")), or (d) a Change in Control (as defined by the Plan). Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 20:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 548 | $53.49 | $29,312.52 |
DisclosureSEC source: 0001171843-18-001902 · form4.xml · nonDerivative · entry 2 Darling Joseph G · CIK 0001433556 · Director · President and CEO; Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,436 F2 · shares: Reflects an aggregate of 548 shares of common stock retained by the Issuer to satisfy tax withholding obligations. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 20:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 7,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-001902 · form4.xml · nonDerivative · entry 1 Darling Joseph G · CIK 0001433556 · Director · President and CEO; Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,984 F1 · security: Restricted stock awards vest in four equal annual installments on March 9, 2018, March 9, 2019, March 9, 2020, and March 9, 2021. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 21,400 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-18-000690 · formfour.xml · derivative · entry 1 Darling Joseph G · CIK 0001433556 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires 2028-01-24 F1 · derivative.exercise_date: The stock options vest in four equal annual installments beginning January 24, 2019. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 20:10 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 41,609 | $0.00 Strike: $51.70 | $0.00 |
DisclosureSEC source: 0001171843-17-004467 · formfour.xml · derivative · entry 2 Darling Joseph G · CIK 0001433556 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,609 Underlying: Common Stock · 41,609 shares Expires 2027-07-27 F2 · derivative.exercise_date: The stock options vest in three equal annual installments beginning July 27, 2018. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 20:10 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 14,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-004467 · formfour.xml · nonDerivative · entry 1 Darling Joseph G · CIK 0001433556 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,506 F1 · security: Restricted stock awards vest in three equal annual installments beginning July 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.